|
Feb 18
|
Hanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancer
|
|
Feb 10
|
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy
|
|
Sep 29
|
RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now
|
|
Sep 25
|
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability
|
|
Jun 21
|
Should You Sell Your Stake in RAPT Therapeutics (RAPT)?
|
|
Jun 14
|
Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround
|
|
May 13
|
Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks
|
|
May 12
|
Here's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation
|
|
May 10
|
RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview
|
|
May 9
|
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
|
|
May 9
|
RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials
|
|
May 9
|
RAPT Therapeutics Reports First Quarter 2024 Financial Results
|
|
Apr 9
|
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
|
|
Apr 9
|
3 Biotech Stocks to Dump Before They Go to Zero
|
|
Mar 22
|
What Makes RAPT Therapeutics (RAPT) an Investment Choice?
|
|
Mar 7
|
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
|
|
Mar 7
|
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 5
|
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
|
|
Feb 20
|
Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests
|
|
Feb 20
|
RAPT Therapeutics Stock Is Down 63%. FDA Halts 2 Studies After Liver Failure.
|